Author

Sara Anca

GlaxoSmithKline (Spain)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alfonso Mendoza-LosanaiD· 1 shared Ángel Santos-Villarejo· 1 shared Charles J. ThompsoniD· 1 shared David Barros-AguirreiD· 1 shared Esther Pérez‐HerrániD· 1 shared Esther Porras de FranciscoiD· 1 shared Helena I. BoshoffiD· 1 shared Joaquín Rullás· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Alfonso Mendoza-LosanaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Sanfetrinem, an oral beta-lactam antibiotic repurposed for the treatment of tuberculosis

Santiago Ramón‐García, Rubén González del Río, María Pilar Arenaz-Callao, Helena I. Boshoff, Joaquín Rullás, Sara Anca, Mónica Cacho, Esther Porras de Francisco, Esther Pérez‐Herrán, Ángel Santos-Villarejo, Alfonso Mendoza-Losana, Santiago B. Ferrer, Charles J. Thompson, David Barros-Aguirre, Robert H. Bates

This paper identifies sanfetrinem cilexetil as a promising oral beta-lactam antibiotic for tuberculosis treatment through preclinical studies showing its activity against Mtb and potential for repurposing.

Drug Resistance Updates · Feb 15, 2025Peer-reviewedMicrobiology